Telaprevir- and boceprevir-based tritherapies in real practice for F3-F4 pretreated hepatitis C virus patients

Table 4 Factors associated with the occurrence of severe adverse events of grade 3 or 4 n (%)

	Severeadverse eventsn = 63	No severeadverse eventsn = 61	P valueunivariate analysis	P valuemultivariate AnalysisOR (95%CI)
Protease inhibitor
Telaprevir	47 (51.7)	43 (48.3)	0.7548	-
Boceprevir	17 (48.6)	18 (51.4)
Genre				0.037
Male	36 (44.4)	45 (55.6)		1.0
Female	27 (62.8)	16 (37.2)	0.0518	2.4 (1.1-5.6)
Liver fibrosis
Metavir F3	15 (42.9)	20 (57.1)	0.2667	-
MetavirF4	48 (53.9)	41 (46.1)
Platelets
Mean × 10³/mm³ (SD)	143.5 (65.43)	191.1 (54.9)	≤ 0.0001	≤ 0.001
< 150 × 10³/mm³	34 (75.6)	11 (24.4)	0.0001	1.0
≥ 150 × 10³/mm³	27 (37.5)	45 (62.5)		5.3 (2.3-12.4)
Albumin, mean, g/L, (SD)	39.4 (4.9)	42 (54.9)	0.0196	-
Bilirubin, median μM/L, (IQR)	13.1 (9.1-19.1)	10.8 (8-13.5)	0.0359	-

The variables initially included in the logistic regression model were those associated with SAEs in the univariate analysis (P value < 0.20). SAEs: Severe adverse events; IQR: Inter-quartile range.